Multiple sclerosis and systemic sclerosis: Efficacy of interferon beta on skin lesions

Annals of the Rheumatic Diseases

Volumn 67, Issue 8, 2008, Pages 1192-1193

  Carrieri, P B ^a,c   Petracca, M ^a   Montella, S ^a   Delfino, M ^a   Sepe, C ^b   Gattoni, A ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Department of Neurological Sciences ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CENTROMERE ANTIBODY; METHYLPREDNISOLONE; SCL 70 ANTIBODY;

ADULT; CASE REPORT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNOLOGY; LETTER; LUNG FIBROSIS; MULTIPLE SCLEROSIS; PATHOGENESIS; POLYARTHRITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RELAPSE; SCLERODERMA; SKIN ULCER; SYSTEMIC SCLEROSIS;

ADJUVANTS, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-BETA; LEG ULCER; MIDDLE AGED; MULTIPLE SCLEROSIS; SCLERODERMA, SYSTEMIC;

EID: 47949117750     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2008.087973     Document Type: Letter

References (8)

1. Chroni E, Paschalis C, Stergiou T, Vlahanastasi C, Andonopoulos AP. Multiple sclerosis in the course of systemic sclerosis. Ann Rheum Dis 2002;61:188.
2. McDonald WI, Compston A, Edan G, Goodkin D,Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444- 52.
4. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
5. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000;11:2445-54.
6. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-9.
7. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007;185:168-74.
8. Rep MH, Schrijver HM, van Lopik T, Hintzen RQ, Roos MT, Adèr HJ, et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999;96:92-100.